United States-based Halodine LLC has collaborated with Emery Pharma, a boutique contract research and development company, it was reported on Thursday.
The collaboration is aimed at advancing the development of Halodine's proprietary antiseptic platform for COVID-19.
The partnership will see Emery Pharma's use its experience in antimicrobial and antiviral screening and drug development, while Halodine is to use its expertise in topical antiviral drug development.
Emery Pharma says that it will leverage its microbiology, virology, and bioanalytical experience to aid in developing this novel product, as well as other drugs to help treat COVID-19.
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial